HIT! High Impact Clinical Trials – Why and How

9 Feb 2025 9 a.m. 10:30 a.m.
Brahmkamal Hall - Plenary Hall
DavidWheeler Chair University College LondonUnited Kingdom
Winston Wing ShingFung Chair Prince of Wales Hospital, Hong KongHong Kong, China

Time Session
9 a.m.
9:18 a.m.
What Have We Learned From CONVINCE?
PeterBlankestijn Oral Abstract Presenter University Medical Center UtrechtNetherlands
9:18 a.m.
9:36 a.m.
Design of the ZEUS Trial: Interleukin-6 Inhibition With Ziltivekimab for Cardiovascular Protection in Chronic Kidney Disease
VladoPerkovic Oral Abstract Presenter University of New South Wales, Sydney, AustraliaAustralia
9:36 a.m.
9:54 a.m.
A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)
JonathanBarratt Oral Abstract Presenter University of Leicester, Leicester, UKUnited Kingdom
9:54 a.m.
10:12 a.m.
Observational Cohort With Embedded Randomized Controlled Trials to Study Pregnancy-Associated Progression of Renal Disease: A Feasibility Study of Dietary Nitrate (Beetroot Juice) to Protect Kidney Function in Pregnant Women With Chronic Kidney Disease
KateBramham Oral Abstract Presenter King's College LondonUnited Kingdom
10:12 a.m.
10:30 a.m.
Design of Randomized Embedded Adaptive Platform Clinical Trial in South Asian Kidney Biopsy-Proven Primary Glomerular Diseases: Multi-Center, Multi-Arm and Multi-Stage
Selvin Sundar RajMani Oral Abstract Presenter Associate Professor in Nephrology, Christian Medical College, Vellore, IndiaIndia
SuceenaAlexander Oral Abstract Presenter Christian Medical College VelloreIndia